Orca Capital reports 1.79M shares in AIM ImmunoTech (NASDAQ: AIM)

Rhea-AI Filing Summary

AIM ImmunoTech Inc. Schedule 13G shows Orca Capital beneficially owns 1,793,999 shares of common stock, representing 9.9% of the class immediately after the issuer's warrant inducement transaction.

The filing states the ownership calculation is based on 17,369,915 shares outstanding after the inducement and excludes 1,333,131 shares issuable upon exercise of common warrants, which are subject to the verbatim "9.99% Blocker".

Insights

Institutional Ownership Analyst

Orca Capital holds a near-10% passive stake under Schedule 13G.

The filing lists 1,793,999 shares and a 9.9% beneficial ownership figure calculated on 17,369,915 shares outstanding after the issuer's warrant inducement transaction. The filing treats warrants of 1,333,131 shares as excluded due to the 9.99% Blocker.

Cash‑flow treatment and plans for disposition are not stated in the excerpt; future filings would disclose any changes in holder status or voting/disposition intentions.

Key Figures

Beneficial ownership: 1,793,999 shares Percent of class: 9.9% Shares outstanding: 17,369,915 shares +2 more

5 metrics

Beneficial ownership 1,793,999 shares Amount beneficially owned per Schedule 13G

Percent of class 9.9% Percent of class based on post-inducement outstanding shares

Shares outstanding 17,369,915 shares Aggregate outstanding immediately after warrant inducement transaction

Warrants issuable 1,333,131 shares Shares issuable upon exercise of common warrants (excluded from calculation)

Beneficial power Sole voting/dispositive power over 1,793,999 Reported sole voting and dispositive power in Item 4

Key Terms

9.99% Blocker, warrant inducement transaction, beneficially owned

3 terms

9.99% Blocker regulatory

"the Reporting Person cannot exercise any of the common warrants to the extent the Reporting Person would beneficially own"

warrant inducement transaction financial

"completion of the Issuer's warrant inducement transaction described in the Issuer's Current Report on Form 8-K filed"

A warrant inducement transaction is when a company issues warrants—options to buy shares at a set price—as a sweetener to persuade investors or creditors to approve a deal, restructuring, or other corporate action. Think of it like giving coupons to convince people to agree to a plan; it can speed approvals but may dilute existing shareholders and change potential future share value, so investors watch these carefully.

beneficially owned regulatory

"Amount beneficially owned: 1,793,999 (b) Percent of class: 9.9 %"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

AIM ImmunoTech Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

00901B303

(CUSIP Number)

05/07/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 00901B303

1

Names of Reporting Persons

Orca Capital AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

GERMANY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,793,999.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,793,999.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,793,999.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 17,369,915 shares of common stock outstanding immediately after giving effect to the completion of the Issuer's warrant inducement transaction described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 8, 2026, and excludes 1,333,131 shares of common stock issuable upon the exercise of common warrants, subject to the 9.99% Blocker (defined below). Pursuant to the terms of the common warrants, the Reporting Person cannot exercise any of the common warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 9.99% of the Issuer's outstanding common stock (the "9.99% Blocker").

SCHEDULE 13G

Item 1.
(a)	Name of issuer: AIM ImmunoTech Inc.
(b)	Address of issuer's principal executive offices: 2117 SW Highway 484, Ocala, FL 34473
Item 2.
(a)	Name of person filing: Orca Capital AG
(b)	Address or principal business office or, if none, residence: Sperlring 2 85276 Hettenshausen Deutschland
(c)	Citizenship: Germany
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP Number(s): 00901B303
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,793,999
(b)	Percent of class: 9.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,793,999
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,793,999
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Orca Capital AG

Signature:	/s/ Thomas Konig
Name/Title:	Thomas Konig/Director
Date:	05/12/2026

FAQ

What stake does Orca Capital report in AIM (AIM)?

Orca Capital reports beneficial ownership of 1,793,999 shares, equal to 9.9% of common stock based on 17,369,915 shares outstanding after the issuer's warrant inducement transaction described in the filing.

How were outstanding shares calculated for the 9.9% figure?

The 9.9% is calculated on an aggregate of 17,369,915 shares outstanding immediately after the issuer's warrant inducement transaction referenced in the filing, per the Schedule 13G statement.

Do warrants affect Orca Capital's ownership percentage?

The filing excludes 1,333,131 shares issuable upon exercise of common warrants from the calculation because the common warrants are subject to the 9.99% Blocker, which limits exercises that would exceed 9.99% ownership.

What voting and disposition powers does Orca Capital report?

Orca Capital reports sole voting power and sole dispositive power over 1,793,999 shares, and reports 0 shared voting or dispositive power in the Schedule 13G filing.

When was the Schedule 13G signed and by whom?

The filing is signed by Thomas Konig as a Director on 05/12/2026, certifying the Schedule 13G disclosure for Orca Capital regarding its holdings in AIM ImmunoTech.